Until the bill was introduced, Kasimov had been assuming that Keryx Biopharmaceuticals (NASDAQ:KERX) would have to make a roughly 33% gross-to-net discount once it became part of the ESRD bundle ... saw its stock price shoot up …
Keryx Biopharmaceuticals KERX, +1.31% shares were up 21% in pre-market trade after the company announced its kidney disease medication met phase 3 endpoints early Tuesday. The ferric citrate medication is intended to treat iron …
To read the entire report visit: www.microstockprofit.com/ads/KERX See what investors are saying about KERX at penny stock forum MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com …
He tripled his position in KERX through purchases made in late February and early March. The stock was trading below $4 around that time. Currently KERX’s latest price is $4.59. Balyasny gained more than 15% in less than two months from …
Keryx Biopharmaceuticals Inc. (KERX) announced Monday morning that a supply interruption ... Shares finished with a loss of 2.64 at $4.72 on the second highest volume of the year. The stock sank to a 3-month low and fell below its 50 …
Keryx Biopharmaceuticals (NASDAQ: KERX) has notched an important win in Europe ... News of the approval bumped the company's stock price slightly higher; if the bullishness continues, it would help reverse a general downward trend in …
KERX), SolarEdge Technologies (NASDAQ: SEDG), Chipotle Mexican Grill (NYSE: CMG), Exelixis (NASDAQ: EXEL). …
Rigrodsky & Long, P.A. reminds shareholders of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) …
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX